Pharmaceuticals Stocks

Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Read More
Pharmaceuticals Stocks

Regeneron Pharmaceuticals Inc Valuation – April 2018 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Read More
Pharmaceuticals Stocks

Regeneron Pharmaceuticals Inc Valuation – November 2016 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Read More
Feature Value Investing Weekly

16 Companies in the Spotlight this Week – 4/19/14

We looked at 16 different companies this week.  Here’s a summary of the ModernGraham Valuations.  For more detailed analysis, click on the name of the company.  Yesterday we also screened all 240 companies in the database to find 5 Undervalued Companies for the Enterprising Investor.  To see more screens of the valuations, be sure to sign […]

Read More
Pharmaceuticals Stocks

Regeneron Pharmaceuticals Inc. (REGN) Annual Valuation – 2014

Regeneron Pharmaceuticals is not suitable for either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company has shown insufficient earnings stability or growth over the ten year historical period, does not pay dividends, and is trading at a high PEmg ratio.

Read More
Back To Top